Higher levels of 3 macular pigments minimize risk of age-related disease.
Ophthalmology Times: December 2020
Study evaluates the impact of surgical procedure on visual outcomes in patients.
A new gene therapy for this patient population targets the ND4 gene mutation.
New options open possibilities for treatment, resulting in better outcomes for patients.
Pandemic forces some to reconsider careers.
A novel ocular corticosteroid is offering hope of quick results for patients.
Check out the latest cartoon!
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
First patient treated in ViaLase’s IDE trial
2
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
3
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
4
Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA
5
.png "Optometry Times"){kind=logo}
